Dr. Alison Moskowitz
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 266
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 235165
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Hematology Lymphoma Group (216 clinicians)
- Msk Harrison (132 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 266
- Services billed
- 799
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 347 | 174 |
| Established patient office or other outpatient visit, 40-54 minutes | 196 | 92 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 16 | 16 |
| Established patient office or other outpatient visit, 20-29 minutes | 15 | 13 |
| Hospital discharge day management, 30 minutes or less | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in New York, NY | 48 |
| Levothyroxine Sodium Other prescribers in New York, NY | 45 |
| Prednisone Other prescribers in New York, NY | 38 |
| Gabapentin Other prescribers in New York, NY | 33 |
| Copiktra (duvelisib) | 32 |
| Bexarotene | 24 |
| Pantoprazole Sodium Other prescribers in New York, NY | 22 |
| Calquence (acalabrutinib maleate) | 21 |
| Fenofibrate (fenofibrate nanocrystallized) Other prescribers in New York, NY | 20 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 4 payments worth $9,221 in total to this clinician.
| Merck Sharp & Dohme LLC | $8,960 |
|---|---|
| Secura Bio, Inc. | $179 |
| Pfizer Inc. | $82.23 |
| Compensation for services other than consulting (speaking, faculty) | $8,960 |
|---|---|
| Food and Beverage | $261 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Sep 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
| Merck Sharp & Dohme LLC Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,480 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 5 companies. The companies reported $2,338,591 in research payments for these studies, mostly to the institutions running them.
- Phase II study of second-line pembrolizumab plus GVD for relapsed or refractory Hodgkin lymphoma
Merck Sharp & Dohme LLC - Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas
Incyte Corporation - Pilot study of pembrolizumab in untreated extranodal, NK/T cell lymphoma, nasal type (SMILE)
Merck Sharp & Dohme LLC - Optimizing dosing of brentuximab vedotin for CD30POSITIVE mycosis fungoides and lymphomatoid papulosis
Pfizer Inc. - STUDY NAME#Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
Merck Sharp & Dohme LLC - STUDY NAME#Phase II study of second-line pembrolizumab plus GVD for relapsed or refractory Hodgkin lymphoma
Merck Sharp & Dohme LLC - STUDY NAME#Pembrolizumab in combination with gemcitabine for previously treated mycosis fungoides and SEzary syndrome# efficacy and characterization of immune response
Merck Sharp & Dohme LLC - STUDY NAME#A phase II study of pembrolizumab and entinostat in patients with relapsed and refractory lymphomas
Merck Sharp & Dohme LLC - An openlabel phase 1 study to evaluate the safety of SGN35T in adults with advanced malignancies
Pfizer Inc. - STUDY NAME#Pembrolizumab in combination with gemcitabine for previously treated mycosis fungoides and S zary syndrome# efficacy and characterization of immune response
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.